Dasiglucagon is a Synthetic Peptide owned by Zealand Pharma, and is involved in 28 clinical trials, of which 18 were completed, 3 are ongoing, and 7 are planned.
Dasiglucagon (ZP-4207) is a glucagon peptide agonist. Glucagon receptor signaling promotes hepatic glucose output by increasing glycogenolysis and gluconeogenesis and by decreasing glycogenesis and glycolysis. Thus, the drug candidate as a glucagon receptor agonist could be effective for the treatment and/or prevention of severe hypoglycemia associated with diabetes.
The revenue for Dasiglucagon is expected to reach a total of $2.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dasiglucagon NPV Report.
Dasiglucagon is originated and owned by Zealand Pharma.
Dasiglucagon (Zegalogue) is an anti hypoglycemic agent. It is formulated as solution for subcutaneous route of administration. Zegalogue is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Dasiglucagon (ZP-4207) is under development for the treatment of congenital hyperinsulinemia (CHI). The drug candidate is administered intravenously, intramuscularly and subcutaneously as a liquid formulation. It was also under development for type 1 diabetes and severe hypoglycemia associated with diabetes and mild to moderate hypoglycemia as glucagon rescue pen, pump use and multiple dose use.
Zealand Pharma Overview
Zealand Pharma (Zealand) is a biotechnology company. It discovers, designs and develops peptide-based medicines that target specialty diseases. The company’s product portfolio comprises glepaglutide which is a long-acting GLP-2 analog in development for the treatment of short bowel syndrome and dasiglucagon is used against type 1 diabetes and congenital hyperinsulinism. It also offers GLP1-GLU which is used against several cardio-metabolic diseases such as heart disease, ischemic stroke and liver diseases. Zealand conducts research and development and in-licensing programs. It has operations in Denmark and the US. ealand is headquartered in Soeborg, Denmark.
The company reported revenues of (Danish Krone) DKK108.6 million for the fiscal year ended December 2021 (FY2021), a decrease of 69.3% over FY2020. The operating loss of the company was DKK784.3 million in FY2021, compared to an operating loss of DKK792.4 million in FY2020. The net loss of the company was DKK1,018.2 million in FY2021, compared to a net loss of DKK846.7 million in FY2020. The company reported revenues of DKK43.7 million for the third quarter ended September 2022, an increase of 54.1% over the previous quarter.
Quick View – Dasiglucagon
|Highest Development Stage|